Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization

Journal of Virology

Volumn 88, Issue 24, 2014, Pages 14278-14288

  Wong, Jason Alexander Ji Xhin ^a   Bhat, Rakesh ^a   Hockman, Darren ^a   Logan, Michael ^a   Chen, Chao ^a   Levin, Aviad ^a   Frey, Sharon E ^b   Belshe, Robert B ^b   Lorne Tyrrell, D ^a   Law, John Lok Man ^a   Houghton, Michael ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; EPITOPE; HEPATITIS C VACCINE; HETERODIMER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1:7; MONOCLONAL ANTIBODY A4; MONOCLONAL ANTIBODY AP33; MONOCLONAL ANTIBODY AR3B; MONOCLONAL ANTIBODY AR4A; MONOCLONAL ANTIBODY AR5A; MONOCLONAL ANTIBODY HC33 4; MONOCLONAL ANTIBODY HC84 26; MONOCLONAL ANTIBODY IGH526; RECOMBINANT HEPATITIS C VIRUS 1 ENVELOPE GLYCOPROTEIN E1E2 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; E1 PROTEIN, HEPATITIS C VIRUS; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING COMPETITION; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CHIMPANZEE; CROSS GENOTYPE NEUTRALIZATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFECTION PREVENTION; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE MAPPING; PHASE 1 CLINICAL TRIAL (TOPIC); VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BLOOD; CLASSIFICATION; CROSS REACTION; EPITOPE MAPPING; GENETICS; GENOTYPE; GOAT; HEPACIVIRUS; IMMUNOLOGY;

HEPATITIS C VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES; GENOTYPE; GOATS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84911489136     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01911-14     Document Type: Article

References (66)

1. WHO. 2013. Hepatitis C. WHO fact sheet 164. WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Liang TJ. 2013. Current progress in development of hepatitis C virus vaccines. Nat. Med. 19:869-878. http://dx.doi.org/10.1038/nm.3183.
3. Thomas DL. 2013. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19:850-858. http://dx.doi.org/10.1038/nm.3184.
4. Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M. 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 32:339-345. http://dx.doi.org/10.1111/j.1478-3231.2011.02684.x.
5. Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, Shaw GM, Perelson AS. 2012. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8:e1002881. http://dx.doi.org/10.1371/journal.ppat.1002881.
6. Farci P. 2011. New insights into the HCV quasispecies and compartmentalization. Semin. Liver Dis. 31:356-374. http://dx.doi.org/10.1055/s-0031-1297925.
7. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. 2003. Memory CD8+T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197:1645-1655. http://dx.doi.org/10.1084/jem.20030239.
8. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-662. http://dx.doi.org/10.1126/science.1088774.
9. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449. http://dx.doi.org/10.1016/S1074-7613(00)80044-8.
10. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:10149-10154. http://dx.doi.org/10.1073/pnas.0403519101.
11. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 104:6025-6030. http://dx.doi.org/10.1073/pnas.0607026104.
12. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. 2005. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79:6023-6034. http://dx.doi.org/10.1128/JVI.79.10.6023-6034.2005.
13. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. 2014. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59:2140-2151. http://dx.doi.org/10.1002/hep.27013.
14. Sautto G, Tarr AW, Mancini N, Clementi M. 2013. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin. Dev. Immunol. 2013:450963. http://dx.doi.org/10.1155/2013/450963.
15. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27. http://dx.doi.org/10.1038/nm1698.
16. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 109:6205-6210. http://dx.doi.org/10.1073/pnas.1114927109.
17. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. 2012. Human monoclonal antibody HCV1 effectively prevents and treatsHCVinfection in chimpanzees. PLoS Pathog. 8:e1002895. http://dx.doi.org/10.1371/journal.ppat.1002895.
18. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. 2011. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53:755-762. http://dx.doi.org/10.1002/hep.24171.
19. Houghton M. 2011. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239:99-108. http://dx.doi.org/10.1111/j.1600-065X.2010.00977.x.
20. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. 2011. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J. Infect. Dis. 204:1186-1190. http://dx.doi.org/10.1093/infdis/jir511.
21. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. 2010. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28:6367-6373. http://dx.doi.org/10.1016/j.vaccine.2010.06.084.
22. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M. 2013. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 8:e59776. http://dx.doi.org/10.1371/journal.pone.0059776.
23. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79:11095-11104. http://dx.doi.org/10.1128/JVI.79.17.11095-11104.2005.
24. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SKH, Taylor GL, Patel AH. 2012. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J. Virol. 86:12923-12932. http://dx.doi.org/10.1128/JVI.02052-12.
25. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJP, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601. http://dx.doi.org/10.1002/hep.21088.
26. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MAA. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 104:16269-16274. http://dx.doi.org/10.1073/pnas.0705522104.
27. Keck Z-Y, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY-J, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SKH. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8:e1002653. http://dx.doi.org/10.1371/journal.ppat.1002653.
28. Keck Z, Wang W, Wang Y, Lau P, Carlsen THR, Prentoe J, Xia J, Patel AH, Bukh J, Foung SKH. 2013. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J. Virol. 87:37-51. http://dx.doi.org/10.1128/JVI.01941-12.
29. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160.
30. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J. 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 84:11905-11915. http://dx.doi.org/10.1128/JVI.01548-10.
31. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973. http://dx.doi.org/10.1128/JVI.01872-07.
32. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitisCvirus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
33. Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377. http://dx.doi.org/10.1002/hep.22673.
34. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003-41012. http://dx.doi.org/10.1074/jbc.M302267200.
35. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025. http://dx.doi.org/10.1093/emboj/cdf529.
36. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941. http://dx.doi.org/10.1126/science.282.5390.938.
37. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18:281-285. http://dx.doi.org/10.1038/nm.2581.
38. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. http://dx.doi.org/10.1038/nature05654.
39. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038/nature07684.
40. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset F-L, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589-595. http://dx.doi.org/10.1038/nm.2341.
41. Martin DN, Uprichard SL. 2013. Identification of transferrin receptor 1 as a hepatitisCvirus entry factor. Proc. Natl. Acad. Sci. U. S. A. 110:10777-10782. http://dx.doi.org/10.1073/pnas.1301764110.
42. Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset F-L, Lavillette D. 2014. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology 59:776-788. http://dx.doi.org/10.1002/hep.26733.
43. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, Abrignani S, Grandi G. 2000. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 74:4824-4830. http://dx.doi.org/10.1128/JVI.74.10.4824-4830.2000.
44. Higginbottom A, Quinn ER, Kuo C, Flint M, Wilson EB, Nicosia A, Monk PN, McKeating J, Levy S. 2000. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 74:3642-3649. http://dx.doi.org/10.1128/JVI.74.8.3642-3649.2000.
45. Drummer HE, Wilson KA, Poumbourios P. 2002. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J. Virol. 76:11143-11147. http://dx.doi.org/10.1128/JVI.76.21.11143-11147.2002.
46. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk PN, Higginbottom A, Levy S, McKeating J. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
47. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85:7005-7019. http://dx.doi.org/10.1128/JVI.00586-11.
48. Kobayashi F, Yamada S, Taguwa S, Kataoka C, Naito S, Hama Y, Tani H, Matsuura Y, Sugahara K. 2012. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj. J. 29:211-220. http://dx.doi.org/10.1007/s10719-012-9388-z.
49. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. 2006. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol. 80:10579-10590. http://dx.doi.org/10.1128/JVI.00941-06.
50. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. 2012. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J. Virol. 86:7256-7267. http://dx.doi.org/10.1128/JVI.07222-11.
51. Agnello V, Ábel G, Elfahal M, Knight GB, Zhang Q-X. 1999. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 96:12766-12771. http://dx.doi.org/10.1073/pnas.96.22.12766.
52. Germi R, Crance J-M, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RWH, Zarski J-P, Drouet E. 2002. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitisCvirus adsorption. J. Med. Virol. 68:206-215. http://dx.doi.org/10.1002/jmv.10196.
53. Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. 2012. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem. 287:31242-31257. http://dx.doi.org/10.1074/jbc.M112.365924.
54. Owsianka AM, Timms JM, Tarr AW, Brown RJP, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitisCvirus that are critical for CD81 binding. J. Virol. 80:8695-8704. http://dx.doi.org/10.1128/JVI.00271-06.
55. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. 2013. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342:1090-1094. http://dx.doi.org/10.1126/science.1243876.
56. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J. 2014. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509:381-384. http://dx.doi.org/10.1038/nature13117.
57. Rychlowska M, Owsianka AM, Foung SKH, Dubuisson J, Bienkowska-Szewczyk K, Patel AH. 2011. Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J. Gen. Virol. 92:2249-2261. http://dx.doi.org/10.1099/vir.0.034314-0.
58. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung S. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74:10407-10416. http://dx.doi.org/10.1128/JVI.74.22.10407-10416.2000.
59. Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SKH, Ball JK, Patel AH. 2008. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89:653-659. http://dx.doi.org/10.1099/vir.0.83386-0.
60. Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JAR, Priem S, Verschoor EJ, Koopman G, Granier C, Dreux M, Cosset FL, Maertens G, Heeney JL. 2011. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J. Infect. Dis. 204:837-844. http://dx.doi.org/10.1093/infdis/jir423.
61. Farci P, Alter H, Wong D, Miller Roger H, Govindarajan S, Engle RE, Shapiro M, Purcell R. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. U. S. A. 91:7792-7796. http://dx.doi.org/10.1073/pnas.91.16.7792.
62. Shimizu YK, Hijikata M, Iwamoto A, Alter H, Purcell R, Yoshikura H. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1494-1500.
63. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344. http://dx.doi.org/10.1126/science.288.5464.339.
64. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu YK, Shapiro M, Alter H, Purcell R. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 93:15394-15399. http://dx.doi.org/10.1073/pnas.93.26.15394.
65. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell R, Yoshikura H. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412. http://dx.doi.org/10.1006/viro.1996.0497.
66. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10.1007/978-1-59745-394-3_4.